Thu, June 27, 2024
[ 12:00 AM ] - WOPRAI
Tue, February 6, 2024
[ 12:00 AM ] - WOPRAI
Tue, August 8, 2023
[ 12:00 AM ] - WOPRAI
Fri, July 28, 2023
[ 12:00 AM ] - WOPRAI
Wed, June 14, 2023
[ 12:00 AM ] - WOPRAI
Fri, May 26, 2023
[ 12:00 AM ] - WOPRAI
Wed, April 26, 2023
[ 12:00 AM ] - WOPRAI
Fri, February 10, 2023
[ 12:00 AM ] - WOPRAI
Fri, February 3, 2023
[ 12:00 AM ] - WOPRAI
Thu, December 1, 2022
[ 12:00 AM ] - WOPRAI
Thu, November 10, 2022
[ 12:00 AM ] - WOPRAI
Mon, October 31, 2022
[ 12:00 AM ] - WOPRAI
Thu, October 27, 2022
[ 12:00 AM ] - WOPRAI
Wed, October 26, 2022
[ 12:00 AM ] - WOPRAI
Mon, September 12, 2022
[ 12:00 AM ] - WOPRAI
Tue, August 9, 2022
[ 12:00 AM ] - WOPRAI
Mon, August 1, 2022
[ 12:00 AM ] - WOPRAI
Thu, July 28, 2022
[ 12:00 AM ] - WOPRAI
Wed, April 28, 2021
[ 12:00 AM ] - WOPRAI
Mon, November 9, 2020
[ 12:00 AM ] - WOPRAI
Tue, June 23, 2020
[ 12:00 AM ] - WOPRAI
Wed, August 14, 2019
Thu, March 21, 2019
Wed, August 8, 2018
Mon, February 5, 2018
Fri, December 18, 2015
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Steve Chesney Initiated (VRTX) at Strong Buy and Held Target at $545 on, Jun 27th, 2024
Steve Chesney of Redburn Atlantic, Initiated "Vertex Pharmaceuticals Incorporated" (VRTX) at Strong Buy and Held Target at $545 on, Jun 27th, 2024.
Steve has made no other calls on VRTX in the last 4 months.
There are 12 other peers that have a rating on VRTX. Out of the 12 peers that are also analyzing VRTX, 2 agree with Steve's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Brian Abrahams of "RBC Capital" Maintained at Hold with Decreased Target to $421 on, Tuesday, June 11th, 2024
- Joseph Stringer of "Needham" Reiterated at Hold on, Tuesday, May 7th, 2024
These are the ratings of the 10 analyists that currently disagree with Steve
- Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $555 on, Monday, June 24th, 2024
- Jasper Hellweg of "Argus Research" Maintained at Strong Buy with Increased Target to $550 on, Monday, June 17th, 2024
- Evan Seigerman of "BMO Capital" Maintained at Buy with Increased Target to $500 on, Friday, May 31st, 2024
- Christopher Raymond of "Piper Sandler" Maintained at Buy with Increased Target to $456 on, Tuesday, May 7th, 2024
- Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $462 on, Tuesday, May 7th, 2024
- Debjit Chattopadhyay of "Guggenheim" Maintained at Strong Buy with Increased Target to $450 on, Thursday, April 18th, 2024
- Colin Bristow of "UBS" Maintained at Strong Buy with Decreased Target to $466 on, Wednesday, April 17th, 2024
- Hartaj Singh of "Oppenheimer" Maintained at Buy and Held Target at $500 on, Monday, April 15th, 2024
- Whitney Ijem of "Canaccord Genuity" Maintained at Strong Sell and Held Target at $371 on, Friday, April 12th, 2024
- Liisa Bayko of "Evercore ISI Group" Upgraded from Hold to Buy and Held Target at $438 on, Thursday, April 11th, 2024
Contributing Sources